CBD and the Opioid Crisis: A New Variable

A 2026 study asks whether adding CBD could help people get pain relief with less opioid medication

Opioids are fantastic at killing pain, but they have an infamous downside. They are addictive and, as a result, overused. Scientists began to wonder if there was a good way to use less of them while still giving patients meaningful relief.

That line of thinking has a name in medicine: opioid-sparing. The idea is that if you could get the same pain relief from a smaller opioid dose, you would reduce total exposure and lower the risk of dependence developing over time. Some researchers believed that cannabidiol (CBD), the non-intoxicating compound found in hemp and cannabis, might be worth testing in that role. A study published in The Journal of Pain in May 2026 did exactly that.

The problem opioid-sparing is trying to solve

More than 80,000 Americans died from opioid overdoses in 2023. That number has dropped slightly from its peak, but chronic pain remains one of the most common reasons people are prescribed opioids in the first place. The tension between managing real, ongoing pain and avoiding dependence is something millions of people navigate every day.

CBD has been studied for pain on its own, with mixed results. Some studies show benefit, others don’t, and the picture is complicated by differences in dose, delivery method, and the type of pain involved. This team asked a more specific question. They didn’t ask whether CBD could replace opioids. They asked whether CBD might make a smaller opioid dose work better.

What makes this study worth paying attention to

Before getting into how the study was designed, it helps to understand what the researchers found, because the structure of the result is what makes it interesting.

CBD enhanced the pain-relieving effect of oxycodone. The combination worked better than the same oxycodone dose on its own. That is the opioid-sparing signal they were looking for.

But here is the part that matters just as much: adding CBD did not make oxycodone more addictive. The drug’s ability to create craving or reinforce its own use did not go up. Pain relief improved; the reward signal did not.

That combination is exactly what researchers hoped for and did not take for granted. Any approach that makes opioids more powerful raises an obvious concern: you might be making them more addictive at the same time. This study, at least in the model they tested, found that the two effects can come apart.

What the researchers actually did

The study was led by Dr. Niall P. Murphy at Texas A&M University College of Dentistry, with a team from the University of Florida and Texas A&M spanning pain research, psychiatry, pharmacology, and pharmaceutics.

They worked with rats that had an established facial pain condition. To measure pain relief, rather than simply recording whether the rat pulled away from a stimulus (a reflex that doesn’t tell you much about how pain affects daily function), they used a behavioral test where the rat had to perform a task despite the discomfort. How willing the animal was to engage tells you more about how much the pain was interfering with its normal behavior.

CBD was given at two doses, and oxycodone was given at a deliberately low dose, one chosen because it sits at the lower end of effective pain relief on its own. They then evaluated three things: how well the combination controlled pain, whether it affected how much the rat moved around (a sign of sedation or agitation), and whether it changed the drug’s pull on the animal.

That last measure worked like this: the rats were placed in a specific area of their environment each time they received the drug. Later, researchers checked whether the rats kept returning to that area on their own. An animal that gravitates toward the drug-associated space is showing you something about craving. It is the same basic principle behind why some people find themselves drawn back to situations connected to past substance use. The rats given the CBD-oxycodone combination did not show a stronger pull toward the drug-associated space than rats given oxycodone alone. The drug did not become more habit-forming.

What the study didn’t prove

The gap between a rat study and something you can apply to your own situation is wide, and it’s worth being direct about that.

The endocannabinoid system works somewhat differently in rodents than in humans. The study used a single pain model, a single oxycodone dose, and CBD doses that don’t translate directly to human use. We don’t know whether the same separation between pain relief and addictive pull would hold at higher doses, or in people with chronic pain conditions different from the one modeled here.

This is a well-designed study that produced a specific signal worth following. It is not a treatment protocol, and it is not a reason to make any changes to a medication regimen on your own.

What this means for you

Most people reading this are not combining CBD with prescription opioids, and nothing in this research suggests you should try to without a doctor involved. Drug interactions are complex, and that conversation belongs with a physician.

What this study speaks to is something many people feel personally: the frustration of living with chronic pain while not wanting to lean on medications that carry real risks. The research field is building a case, study by study, that CBD may have a meaningful role in pain management as something that works alongside other approaches, not as a replacement for them.

For people using CBD topically for localized pain, the mechanism is different from what this study examined. But the underlying direction is consistent: CBD interacts with the body’s endocannabinoid system in ways that affect how pain signals are processed, and researchers are still working out when and how that is most useful.

There aren’t clean answers yet. That’s what makes it worth following.

---

About the original study

Title: Selective opioid-sparing effects of cannabidiol on opioid analgesia in rats

Published: May 2026

Authors:

• Ariana C. Brice-Tutt — Department of Orthodontics, College of Dentistry, University of Florida
• Niall P. Murphy, Ph.D. — Department of Biomedical Sciences, Texas A&M University College of Dentistry (corresponding author)
• Barry Setlow, Ph.D. — Department of Psychiatry, University of Florida; McKnight Brain Institute
• Abhisheak Sharma, Ph.D. — Department of Pharmaceutics, University of Florida College of Pharmacy
• John K. Neubert, D.D.S., Ph.D. — Department of Biomedical Sciences, Texas A&M University College of Dentistry

Link: https://pubmed.ncbi.nlm.nih.gov/42219047/

---